A PYMNTS Company

Mexico: COFECE says more generic drug competition is needed

By  |  August 10, 2017

The low participation of generics in the drug market generates higher prices and additional annual expenses to Mexicans of 2.5 billion pesos (US$139 million), said the Federal Commission for Economic Competition (Cofece).

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Commission President, Alejandra Palacios, said that they identified four distortions that prevent the greater participation of actors in the medical market: entry of generics has been slow; the expiration of patents has not generated competition; there are legal strategies to extend these patents, and entry of generics has not not translated into better prices for the consumer.

    President Commissioner Palacios said that promoting the use of generics is required to improve the participation of companies in the market. Also, the industry must reduce processing times for purchases and payments of medicines in the public sector.

    Full Content: Informador

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.